Hugel Aesthetics is deploying a direct sales force in the US to drive Letybo adoption and rolling out a K-TOX campaign—a branded positioning effort that leans into Korean aesthetic credentials. The move signals serious commitment to compete against entrenched players like AbbVie/Allergan and Galderma in the North American market.
Injectables
Hugel Builds US Direct Sales Force for Letybo, Launches K-TOX Campaign
South Korean toxin maker escalates stateside presence with dedicated field team and branded marketing push.
1-YEAR MOVE
ABBV▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Hugel is backing Letybo with a direct US sales force—a costly bet that signals confidence in competing against Allergan and Galderma.
Letybo is Hugel's botulinum toxin formulation, already approved in multiple markets. A dedicated sales team typically indicates the company believes it can capture share through physician relationships and education rather than relying solely on distributor networks. The K-TOX branding angle—playing on the global cachet of Korean beauty and cosmetic procedures—is a differentiation play in a market where toxin efficacy is largely commoditized and prescriber loyalty hinges on rebate programs, ease of ordering, and clinical support.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.